Beaver Sandra reported option exercise involving 6,747 derivative units of TANDEM DIABETES CARE INC at $0.00 for $0 on Nov 15, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Director
DIR
Filed Nov 17, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
6,747Restricted Stock Unit
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
13,495Direct
Trade date
Nov 15, 2026Option exercise
Filed
Nov 17, 2026, 6:11 PM ET2-day reporting delay
Accession
0001438133-26-000159Code M · Transaction 404429
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 15, 2026Option exercise6,747$0.00$0Trade 404428
2 transaction rows in this filing. Joint filers share the same rows.

TNDM price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
TNDM · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 24, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −4.8%1w ago −0.8%1d ago +18%
Returns since7d30d90d180d1y

Footnotes in full

F1: Awarded on November 7, 2025 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F2: Each Restricted Stock Unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F3: One-third of the RSUs granted on November 7, 2025 vested on November 15, 2026, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.